"Theolytics Secures £19M Funding for Ovarian Cancer Therapy Development"
Theolytics Closes £19M Funding Round
Theolytics Raises £19M in Funding for Oncolytic Viral Therapies
Key Highlights:
- Funding Round: Theolytics, a biotech company focused on developing oncolytic viral therapies, raised £19M in funding.
- Investors: Sound Bioventures, M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, and the University of Oxford participated in the funding round.
- Lead Program: Theolytics plans to advance its lead oncolytic adenovirus, THEO-260, into clinical trials for ovarian cancer treatment.
Theolytics' Target Market
- Target Market: Patients with ovarian cancer, particularly those with limited treatment options.
- Healthcare Providers and Specialists: Oncologists, gynecologists, and other healthcare professionals specializing in cancer treatment.
- Research Institutions and Biotech Companies: Collaborations with research institutions and biotech companies for further development and clinical trials.
What Theolytics Needs to Buy
- Clinical Research and Development Services: Collaborating with research organizations and clinical trial experts for advancing their oncolytic viral therapies.
- Manufacturing and Supply Chain Solutions: Partnering with manufacturers for the production of their therapies and managing a reliable supply chain.
- Marketing and Sales Expertise: Engaging with marketing agencies and sales experts to effectively reach their target market and healthcare providers.